Diversity of angiogenesis among malignant bone tumors

Kubo,Tadahiko; Shimose,Shoji; Fujimori,Jun; Arihiro,Koji; Ochi,Mitsuo

doi:10.3892/mco.2012.11

Diversity of angiogenesis among malignant bone tumors

Authors:
- Tadahiko Kubo
- Shoji Shimose
- Jun Fujimori
- Koji Arihiro
- Mitsuo Ochi
View Affiliations

Affiliations: Department of Orthopaedic Surgery, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima 734-8551, Japan, Department of Anatomical Pathology, Hiroshima University Hospital, Minami-ku, Hiroshima 734-8551, Japan
Published online on: August 10, 2012 https://doi.org/10.3892/mco.2012.11
Pages: 131-136

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Several studies have demonstrated that angiogenesis assessed by microvessel density (MVD) correlates with patient prognosis in various types of cancer, whereas data regarding the relevance of angiogenesis and prognosis in malignant bone tumors are scarce and controversial. The aim of this study was to examine MVD in representative malignant bone tumors, such as osteosarcoma, chondrosarcoma and Ewing's sarcoma, in order to clarify the role of angiogenesis in prognosis. A total of 69 patients with malignant bone tumors, including 44 osteosarcomas, 20 chondrosarcomas and 5 Ewing's sarcomas, were reviewed retrospectively and treated at our hospital between 1980 and 2007. Biopsy or pre-chemotherapy surgical specimens were immunohistochemically stained with anti-CD34 antibody. The MVD values of osteosarcomas and Ewing's sarcomas were significantly higher compared to chondrosarcoma. In osteosarcomas with high MVD, American Joint Committee on Cancer stage IIA, good histological response to chemotherapy was significantly correlated with better disease-free survival, while MVD was closely associated with age and chemotherapy response. In chondrosarcomas, the surgical margin (marginal and intralesional), MVD (high), tumor size (≥8) and histological grade (grades 2 and 3) significantly correlated with a shorter disease-free survival, while MVD was closely associated with age and histological grade. These findings showed that osteosarcomas and Ewing's sarcomas were hypervascular, compared to chondrosarcomas. In osteosarcomas, hypervascularity induced good chemotherapy response, leading to better prognosis, while in chondrosarcomas, high MVD was associated with histological grade and predicted poor prognosis.

View Figures

View References

1.	Bacci G, Briccoli A, Ferrari S, et al: Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli’s 4th protocol. Eur J Cancer. 37:2030–2039. 2001.
2.	Bielack SS, Kempf-Bielack B, Delling G, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 20:776–790. 2002.
3.	Paulussen M, Fröhlich B and Jürgens H: Ewing tumour: incidence, prognosis and treatment options. Paediatr Drugs. 3:899–913. 2001.
4.	Paulussen M, Ahrens S, Dunst J, et al: Localized Ewing tumor of bone: final results of the cooperative Ewing’s Sarcoma Study CESS 86. J Clin Oncol. 19:1818–1829. 2001.
5.	Rizzo M, Ghert MA, Harrelson JM and Scully SP: Chondrosarcoma of bone: analysis of 108 cases and evaluation for predictors of outcome. Clin Orthop Relat Res. 391:224–233. 2001.
6.	Welkerling H, Kratz S, Ewerbeck V and Delling G: A reproducible and simple grading system for classical chondrosarcomas. Analysis of 35 chondrosarcomas and 16 enchondromas with emphasis on recurrence rate and radiological and clinical data. Virchows Arch. 443:725–733. 2003.
7.	Folkman J, Watson K, Ingber D and Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 339:58–61. 1989.
8.	Hasan J, Byers R and Jayson GC: Intra-tumoural microvessel density in human solid tumours. Br J Cancer. 86:1566–1577. 2002.
9.	Kawaguchi N, Matumoto S and Manabe J: New method of evaluating the surgical margin and safety margin for musculoskeletal sarcoma, analysed on the basis of 457 surgical cases. J Cancer Res Clin Oncol. 121:555–563. 1995.
10.	Huvos AG: Bone Tumors: Diagnosis, Treatment, and Prognosis. 2nd edition. W.B. Saunders; Philadelphia: pp. 85–155. 1991
11.	Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 324:1–8. 1991.
12.	Iwamoto Y, Tanaka K, Isu K, et al: Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop Sci. 14:397–404. 2009.
13.	Kimura H, Tsuchiya H, Shirai T, et al: Caffeine-potentiated chemotherapy for metastatic osteosarcoma. J Orthop Sci. 14:556–565. 2009.
14.	Mikulić D, Ilić I, Cepulić M, et al: Tumor angiogenesis and outcome in osteosarcoma. Pediatr Hematol Oncol. 21:611–619. 2004.
15.	Kaya M, Wada T, Nagoya S, Sasaki M, Matsumura T and Yamashita T: The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma. J Bone Joint Surg Br. 91:784–788. 2009.
16.	Mantadakis E, Kim G, Reisch J, et al: Lack of prognostic significance of intratumoral angiogenesis in nonmetastatic osteosarcoma. J Pediatr Hematol Oncol. 23:286–289. 2001.
17.	Ek ET, Ojaimi J, Kitagawa Y and Choong PF: Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma? Oncol Rep. 16:17–23. 2006.
18.	Ek ET, Ojaimi J, Kitagawa Y and Choong PF: Outcome of patients with osteosarcoma over 40 years of age: is angiogenesis a marker of survival? Int Semin Surg Oncol. 3:72006.
19.	Kreuter M, Bieker R, Bielack SS, et al: Prognostic relevance of increased angiogenesis in osteosarcoma. Clin Cancer Res. 10:8531–8537. 2004.
20.	Ayala G, Liu C, Nicosia R, Horowitz S and Lackman R: Microvasculature and VEGF expression in cartilaginous tumors. Hum Pathol. 31:341–346. 2000.
21.	McGough RL, Aswad BI and Terek RM: Pathologic neovascularization in cartilage tumors. Clin Orthop Relat Res. 397:76–82. 2002.
22.	McGough RL, Lin C, Meitner P, Aswad BI and Terek RM: Angiogenic cytokines in cartilage tumors. Clin Orthop Relat Res. 397:62–69. 2002.
23.	Kalinski T, Sel S, Kouznetsova I, Röpke M and Roessner A: Heterogeneity of angiogenesis and blood vessel maturation in cartilage tumors. Pathol Res Pract. 205:339–345. 2009.
24.	Nakagawa SA, Lopes A, Lopes de Carvalho A, et al: Nitric oxide synthases, cyclooxygenase-2, nitrotyrosine, and angiogenesis in chondrosarcoma and their relation to prognosis. J Bone Joint Surg Am. 92:1738–1746. 2010.
25.	Riedel RF, Larrier N, Dodd L, Kirsch D, Martinez S and Brigman BE: The clinical management of chondrosarcoma. Curr Treat Options Oncol. 10:94–106. 2009.